HIF-1α/2α were proven to be differently regulated in a number of tumors and seem to have a different impact on tumor behavior and patient outcome in neuroblastoma [222, 223], glioma/glioblastoma [154, 158] as well as breast [224] and non-small cell lung carcinoma [225, 226]. This evidence concerns the gene HIF1A and glioblastoma.